Stay updated on Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial
Sign up to get notified when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.

Latest updates to the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page now includes an operating-status notice and a version update to v3.2.0, while removing the previous v3.1.0 reference.SummaryDifference2%
- Check17 days agoChange DetectedRemoved several disease/classification terms (neoplasms and carcinoma-related entries) and added a version update to v3.1.0.SummaryDifference0.5%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe page revision updates from v3.0.1 to v3.0.2. The 'Back to Top' UI element has been removed.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated from version v3.0.0 to v3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.1%
- Check45 days agoChange DetectedThe web page has added significant medical content related to various diseases, particularly focusing on female urogenital conditions and neoplasms, while removing several related resources and terms.SummaryDifference4%
- Check60 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.